Here are 1-3 brief analogies to describe Evommune:

• An emerging Regeneron or Sanofi, but specializing in novel oral and biologic treatments for chronic inflammatory conditions like hives and eczema.
• A clinical-stage AbbVie, dedicated to developing the next generation of therapies for a broad range of chronic inflammatory diseases.

• EVO756: An oral small molecule antagonist of MRGPRX2, currently in Phase 2 development for chronic spontaneous urticaria (CSU) and atopic dermatitis (AD).
• EVO301: A long-acting fusion protein designed to neutralize IL-18, currently in Phase 2 development for atopic dermatitis (AD) and planned for ulcerative colitis (UC).

Based on the provided background information, Evommune (EVMN) is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases. The company is currently advancing product candidates (EVO756 and EVO301) through Phase 2 clinical trials.

As a clinical-stage company, Evommune does not yet have commercially approved products available for sale. Therefore, it does not currently have major customers, either other companies or individuals, to whom it sells therapies.

Its primary activities involve research and development, conducting clinical trials, and seeking regulatory approval for its drug candidates. If successful, its therapies would eventually be prescribed to individual patients through healthcare providers, but this stage has not yet been reached.

Luis Peña, Co-Founder, President & Chief Executive Officer

Luis Peña is a co-founder of Evommune and has served as its President and Chief Executive Officer since April 2020. He brings over 30 years of experience in the biotech and pharmaceutical industries. Prior to co-founding Evommune, Mr. Peña co-founded Dermira in August 2010, where he served as Chief Development Officer and led its R&D group through the company's acquisition by Eli Lilly & Company for $1.1 billion in 2020. Before Dermira, he held positions as Vice President, Head of Global Prescription Development at Stiefel (a GSK company), and Senior Vice President, Portfolio Planning and Management at Stiefel Laboratories before its acquisition by GSK. His career also includes leadership roles in portfolio management and product development at Connetics and Theravance, as well as positions in manufacturing and R&D at Genentech.

Kyle Carver, Chief Financial Officer

Kyle Carver is the Chief Financial Officer of Evommune. He joined Evommune from Kadmon Holdings, Inc., a Sanofi Company, where he was the Chief Accounting Officer. In this role, he managed all financial and accounting operations, including Kadmon's transition to a public company following its 2016 initial public offering, through the approval and commercialization of REZUROCK® in 2021. Mr. Carver was instrumental in raising over $500 million through various offerings and played a key role in the deal-making activities, including Sanofi's $1.9 billion acquisition of Kadmon in November 2021. Earlier in his career, he held a senior position at KPMG, where he advised numerous life science clients. He is a Certified Public Accountant.

Dr. Eugene A. Bauer, M.D., Co-Founder, Chief Medical Officer and Director

Dr. Eugene A. Bauer is a co-founder of Evommune and serves as its Chief Medical Officer and a Director. He is also a former executive of Dermira.

Dr. Jeegar Patel, Ph.D., Chief Scientific Officer

Dr. Jeegar Patel was appointed Chief Scientific Officer of Evommune in October 2022. Before joining Evommune, he was the Senior Vice President, Research and Nonclinical Development at Kadmon Holdings, Inc. (a Sanofi Company), where he led the research and development organization with a focus on fibrosis, immunology, and immuno-oncology. Dr. Patel contributed to multiple IND and NDA filings, including the development and approval of Rezurock®, which preceded Sanofi's $1.9 billion acquisition of Kadmon in late 2021. Prior to Kadmon, he was a Nonclinical Development Project Leader at ImClone Systems (acquired by Eli Lilly in 2008), where he supported the approval of Cyramza®, Portrazza®, and Lartruvo®.

Gregory S. Moss, Esq., Chief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer

Gregory S. Moss serves as Evommune's Chief Business & Legal Officer, Corporate Secretary, and Chief Compliance Officer.

The key risks to Evommune's business include:

1. Clinical Trial Failure and Regulatory Uncertainty: Evommune's success is critically dependent on its ability to successfully complete clinical trials for its lead product candidates, EVO756 and EVO301, and obtain regulatory approval. Both candidates are currently in Phase 2 trials, with initial results expected in 2026. Failure to demonstrate safety and efficacy in these or subsequent trials, or an inability to obtain necessary regulatory approvals, would severely impact the company's prospects.

2. Intense Competition: Evommune operates in a highly competitive market for chronic inflammatory diseases, facing competition from established pharmaceutical companies and other biotechnology firms. The company itself notes comparisons to existing treatments like omalizumab and barzolvolimab. The emergence of new therapies or more effective existing treatments could limit the market potential and commercial success of Evommune's product candidates, even if they are approved.

3. Dependence on a Limited Product Pipeline: Evommune's near-term business and future growth are heavily reliant on the successful development and commercialization of its two primary clinical-stage product candidates, EVO756 and EVO301. While the company has plans for additional indications and preclinical programs, a failure in either of these lead programs would significantly hinder its ability to generate revenue and sustain operations in the short to medium term.

Evommune (EVMN) is developing therapies for chronic inflammatory diseases, with its main product candidates, EVO756 and EVO301, targeting significant addressable markets.

EVO756 Addressable Markets:

• Chronic Spontaneous Urticaria (CSU): The global market for Chronic Spontaneous Urticaria is estimated to be valued at approximately USD 2.66 billion in 2025 and is projected to reach USD 5.49 billion by 2032. In the 7MM (United States, EU4, and Japan), the market was approximately USD 2 billion in 2025 and is projected to grow to USD 7.555 billion by 2034. The U.S. market alone was approximately USD 1 billion in 2024.
• Atopic Dermatitis (AD): The global atopic dermatitis market size is projected to be USD 19.38 billion in 2025 and is expected to reach USD 33.29 billion by 2031. Another source estimates the global market at USD 6.62 billion in 2025, growing to USD 13.96 billion by 2035. The 7MM market for Atopic Dermatitis was around USD 17 billion in 2023. North America held the largest share of the global atopic dermatitis market in 2025, accounting for 41.30% of the market.

EVO301 Addressable Markets:

• Atopic Dermatitis (AD): As mentioned above, the global atopic dermatitis market size is projected to be USD 19.38 billion in 2025 and is expected to reach USD 33.29 billion by 2031.
• Ulcerative Colitis (UC): The global ulcerative colitis treatment market is anticipated to grow from USD 11.01 billion in 2025 to USD 15.81 billion by 2034. Another estimate places the global market at USD 10.56 billion in 2025, expected to reach USD 13.59 billion by 2031. The Ulcerative Colitis market size in the 7MM was approximately USD 8.4 billion in 2023. The U.S. market accounted for approximately USD 5.9 billion in 2023. North America commanded 43.25% of the global ulcerative colitis market revenue in 2025.

Here are 3-5 expected drivers of future revenue growth for Evommune (EVMN) over the next 2-3 years:

1. Advancement of EVO756 in Chronic Spontaneous Urticaria (CSU): Evommune expects to report initial results from its Phase 2b dose-ranging trial of EVO756 in CSU in the first half of 2026. Positive clinical data and progression to later stages of development for this lead product candidate could significantly increase its commercial potential and attract partnerships or investment, which are drivers of future revenue.
2. Progression of EVO756 in Atopic Dermatitis (AD): The company initiated a Phase 2b dose-ranging trial for EVO756 in moderate-to-severe AD in August 2025, with initial results anticipated in the second half of 2026. Successful outcomes in this large market could pave the way for a significant new revenue stream.
3. Clinical Development of EVO301 in Atopic Dermatitis (AD): Evommune began a Phase 2 trial for EVO301 in adult patients with moderate-to-severe AD in March 2025, with initial results expected in the first half of 2026. The successful development of a second clinical-stage product candidate in a major inflammatory disease market represents a crucial driver for future revenue.
4. Expansion of EVO301 into Ulcerative Colitis (UC): The company plans to initiate a Phase 2 trial of EVO301 in moderate-to-severe UC patients in 2026. Entry into the ulcerative colitis market, a significant chronic inflammatory disease, represents a new potential market expansion for EVO301 and a driver of long-term revenue growth.
5. Pipeline Expansion into Additional Chronic Inflammatory Diseases: Evommune intends to evaluate both EVO756 and EVO301 in additional indications where their respective mechanisms of action are key drivers of disease (e.g., EVO756 in other neuroinflammatory conditions; EVO301 in Crohn's disease and other IL-18 driven conditions). This strategic expansion of their product candidates into new therapeutic areas provides multiple avenues for future revenue generation beyond their current primary indications.

Share Issuance

• Evommune completed its Initial Public Offering (IPO) on November 6, 2025, raising approximately $150 million by selling about 9.38 million shares at $16 per share.
• In February 2026, the company announced a $125 million private placement, issuing common stock to new and existing institutional investors.
• The number of shares outstanding for Evommune increased by 306.86% in one year.

Inbound Investments

• In February 2026, Evommune secured a $125 million private placement from a select group of new and existing mutual funds and dedicated healthcare institutional investors.
• Evommune's revenue in 2025 saw an increase due to a licensing collaboration for EVO756 in Japan.

Capital Expenditures

• Capital expenditures for Evommune in the last 12 months totaled -$235,000.
• In the fourth quarter of 2025, Evommune invested $104,000 in capital expenditures, focusing on funding long-term assets and infrastructure.
• Proceeds from the IPO are allocated to funding Phase 2 clinical trials for EVO756 and EVO301, strengthening operational capabilities, and supporting expansion into additional indications.